

Global Neuroblastoma Chemotherapy Drugs Market Growth 2023-2029

<https://marketpublishers.com/r/GED80B0FE4DEEN.html>

Date: February 2023

Pages: 102

Price: US\$ 3,660.00 (Single User License)

ID: GED80B0FE4DEEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

LPI (LP Information)' newest research report, the "Neuroblastoma Chemotherapy Drugs Industry Forecast" looks at past sales and reviews total world Neuroblastoma Chemotherapy Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Neuroblastoma Chemotherapy Drugs sales for 2023 through 2029. With Neuroblastoma Chemotherapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Neuroblastoma Chemotherapy Drugs industry.

This Insight Report provides a comprehensive analysis of the global Neuroblastoma Chemotherapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neuroblastoma Chemotherapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Neuroblastoma Chemotherapy Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroblastoma Chemotherapy Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroblastoma Chemotherapy Drugs.

The global Neuroblastoma Chemotherapy Drugs market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Neuroblastoma Chemotherapy Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Neuroblastoma Chemotherapy Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Neuroblastoma Chemotherapy Drugs is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Neuroblastoma Chemotherapy Drugs players cover Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuroblastoma Chemotherapy Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Cyclophosphamide

Cisplatin or Carboplatin

Vincristine

Doxorubicin (Adriamycin)

Etoposide

Other

Segmentation by application

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Baxter Healthcare

Ingenus Pharmaceuticals

ANI Pharmaceuticals

Teva Pharmaceuticals

Qilu Pharmaceutical

Pfizer

Hikma Pharmaceuticals

Fresenius Kabi

Accord Healthcare

Viatis

Key Questions Addressed in this Report

What is the 10-year outlook for the global Neuroblastoma Chemotherapy Drugs market?

What factors are driving Neuroblastoma Chemotherapy Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Neuroblastoma Chemotherapy Drugs market opportunities vary by end market size?

How does Neuroblastoma Chemotherapy Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Neuroblastoma Chemotherapy Drugs Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Neuroblastoma Chemotherapy Drugs by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Neuroblastoma Chemotherapy Drugs by Country/Region, 2018, 2022 & 2029
- 2.2 Neuroblastoma Chemotherapy Drugs Segment by Type
 - 2.2.1 Cyclophosphamide
 - 2.2.2 Cisplatin or Carboplatin
 - 2.2.3 Vincristine
 - 2.2.4 Doxorubicin (Adriamycin)
 - 2.2.5 Etoposide
 - 2.2.6 Other
- 2.3 Neuroblastoma Chemotherapy Drugs Sales by Type
 - 2.3.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Neuroblastoma Chemotherapy Drugs Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Neuroblastoma Chemotherapy Drugs Sale Price by Type (2018-2023)
- 2.4 Neuroblastoma Chemotherapy Drugs Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Other
- 2.5 Neuroblastoma Chemotherapy Drugs Sales by Application

2.5.1 Global Neuroblastoma Chemotherapy Drugs Sale Market Share by Application (2018-2023)

2.5.2 Global Neuroblastoma Chemotherapy Drugs Revenue and Market Share by Application (2018-2023)

2.5.3 Global Neuroblastoma Chemotherapy Drugs Sale Price by Application (2018-2023)

3 GLOBAL NEUROBLASTOMA CHEMOTHERAPY DRUGS BY COMPANY

3.1 Global Neuroblastoma Chemotherapy Drugs Breakdown Data by Company

3.1.1 Global Neuroblastoma Chemotherapy Drugs Annual Sales by Company (2018-2023)

3.1.2 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Company (2018-2023)

3.2 Global Neuroblastoma Chemotherapy Drugs Annual Revenue by Company (2018-2023)

3.2.1 Global Neuroblastoma Chemotherapy Drugs Revenue by Company (2018-2023)

3.2.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Company (2018-2023)

3.3 Global Neuroblastoma Chemotherapy Drugs Sale Price by Company

3.4 Key Manufacturers Neuroblastoma Chemotherapy Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Neuroblastoma Chemotherapy Drugs Product Location Distribution

3.4.2 Players Neuroblastoma Chemotherapy Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR NEUROBLASTOMA CHEMOTHERAPY DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Neuroblastoma Chemotherapy Drugs Market Size by Geographic Region (2018-2023)

4.1.1 Global Neuroblastoma Chemotherapy Drugs Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Neuroblastoma Chemotherapy Drugs Annual Revenue by Geographic

Region (2018-2023)

4.2 World Historic Neuroblastoma Chemotherapy Drugs Market Size by Country/Region (2018-2023)

4.2.1 Global Neuroblastoma Chemotherapy Drugs Annual Sales by Country/Region (2018-2023)

4.2.2 Global Neuroblastoma Chemotherapy Drugs Annual Revenue by Country/Region (2018-2023)

4.3 Americas Neuroblastoma Chemotherapy Drugs Sales Growth

4.4 APAC Neuroblastoma Chemotherapy Drugs Sales Growth

4.5 Europe Neuroblastoma Chemotherapy Drugs Sales Growth

4.6 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Growth

5 AMERICAS

5.1 Americas Neuroblastoma Chemotherapy Drugs Sales by Country

5.1.1 Americas Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023)

5.1.2 Americas Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023)

5.2 Americas Neuroblastoma Chemotherapy Drugs Sales by Type

5.3 Americas Neuroblastoma Chemotherapy Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Neuroblastoma Chemotherapy Drugs Sales by Region

6.1.1 APAC Neuroblastoma Chemotherapy Drugs Sales by Region (2018-2023)

6.1.2 APAC Neuroblastoma Chemotherapy Drugs Revenue by Region (2018-2023)

6.2 APAC Neuroblastoma Chemotherapy Drugs Sales by Type

6.3 APAC Neuroblastoma Chemotherapy Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Neuroblastoma Chemotherapy Drugs by Country

7.1.1 Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023)

7.1.2 Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023)

7.2 Europe Neuroblastoma Chemotherapy Drugs Sales by Type

7.3 Europe Neuroblastoma Chemotherapy Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs by Country

8.1.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023)

8.1.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023)

8.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type

8.3 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Neuroblastoma Chemotherapy Drugs

10.3 Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs

10.4 Industry Chain Structure of Neuroblastoma Chemotherapy Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Neuroblastoma Chemotherapy Drugs Distributors

11.3 Neuroblastoma Chemotherapy Drugs Customer

12 WORLD FORECAST REVIEW FOR NEUROBLASTOMA CHEMOTHERAPY DRUGS BY GEOGRAPHIC REGION

12.1 Global Neuroblastoma Chemotherapy Drugs Market Size Forecast by Region

12.1.1 Global Neuroblastoma Chemotherapy Drugs Forecast by Region (2024-2029)

12.1.2 Global Neuroblastoma Chemotherapy Drugs Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Neuroblastoma Chemotherapy Drugs Forecast by Type

12.7 Global Neuroblastoma Chemotherapy Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Baxter Healthcare

13.1.1 Baxter Healthcare Company Information

13.1.2 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Baxter Healthcare Main Business Overview

13.1.5 Baxter Healthcare Latest Developments

13.2 Ingenus Pharmaceuticals

13.2.1 Ingenus Pharmaceuticals Company Information

13.2.2 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Ingenus Pharmaceuticals Main Business Overview

13.2.5 Ingenus Pharmaceuticals Latest Developments

13.3 ANI Pharmaceuticals

13.3.1 ANI Pharmaceuticals Company Information

13.3.2 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 ANI Pharmaceuticals Main Business Overview

13.3.5 ANI Pharmaceuticals Latest Developments

13.4 Teva Pharmaceuticals

13.4.1 Teva Pharmaceuticals Company Information

13.4.2 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Teva Pharmaceuticals Main Business Overview

13.4.5 Teva Pharmaceuticals Latest Developments

13.5 Qilu Pharmaceutical

13.5.1 Qilu Pharmaceutical Company Information

13.5.2 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Qilu Pharmaceutical Main Business Overview

13.5.5 Qilu Pharmaceutical Latest Developments

13.6 Pfizer

13.6.1 Pfizer Company Information

13.6.2 Pfizer Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Pfizer Main Business Overview

13.6.5 Pfizer Latest Developments

13.7 Hikma Pharmaceuticals

13.7.1 Hikma Pharmaceuticals Company Information

13.7.2 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product

Portfolios and Specifications

13.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Hikma Pharmaceuticals Main Business Overview

13.7.5 Hikma Pharmaceuticals Latest Developments

13.8 Fresenius Kabi

13.8.1 Fresenius Kabi Company Information

13.8.2 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Fresenius Kabi Main Business Overview

13.8.5 Fresenius Kabi Latest Developments

13.9 Accord Healthcare

13.9.1 Accord Healthcare Company Information

13.9.2 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Accord Healthcare Main Business Overview

13.9.5 Accord Healthcare Latest Developments

13.10 Viatris

13.10.1 Viatris Company Information

13.10.2 Viatris Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

13.10.3 Viatris Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Viatris Main Business Overview

13.10.5 Viatris Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Neuroblastoma Chemotherapy Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Neuroblastoma Chemotherapy Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Cyclophosphamide

Table 4. Major Players of Cisplatin or Carboplatin

Table 5. Major Players of Vincristine

Table 6. Major Players of Doxorubicin (Adriamycin)

Table 7. Major Players of Etoposide

Table 8. Major Players of Other

Table 9. Global Neuroblastoma Chemotherapy Drugs Sales by Type (2018-2023) & (K Units)

Table 10. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2018-2023)

Table 11. Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2018-2023) & (\$ million)

Table 12. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2018-2023)

Table 13. Global Neuroblastoma Chemotherapy Drugs Sale Price by Type (2018-2023) & (US\$/Unit)

Table 14. Global Neuroblastoma Chemotherapy Drugs Sales by Application (2018-2023) & (K Units)

Table 15. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2018-2023)

Table 16. Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2018-2023)

Table 17. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2018-2023)

Table 18. Global Neuroblastoma Chemotherapy Drugs Sale Price by Application (2018-2023) & (US\$/Unit)

Table 19. Global Neuroblastoma Chemotherapy Drugs Sales by Company (2018-2023) & (K Units)

Table 20. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Company (2018-2023)

Table 21. Global Neuroblastoma Chemotherapy Drugs Revenue by Company

(2018-2023) (\$ Millions)

Table 22. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Company (2018-2023)

Table 23. Global Neuroblastoma Chemotherapy Drugs Sale Price by Company (2018-2023) & (US\$/Unit)

Table 24. Key Manufacturers Neuroblastoma Chemotherapy Drugs Producing Area Distribution and Sales Area

Table 25. Players Neuroblastoma Chemotherapy Drugs Products Offered

Table 26. Neuroblastoma Chemotherapy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Neuroblastoma Chemotherapy Drugs Sales by Geographic Region (2018-2023) & (K Units)

Table 30. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Geographic Region (2018-2023)

Table 31. Global Neuroblastoma Chemotherapy Drugs Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 32. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Geographic Region (2018-2023)

Table 33. Global Neuroblastoma Chemotherapy Drugs Sales by Country/Region (2018-2023) & (K Units)

Table 34. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Country/Region (2018-2023)

Table 35. Global Neuroblastoma Chemotherapy Drugs Revenue by Country/Region (2018-2023) & (\$ millions)

Table 36. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country/Region (2018-2023)

Table 37. Americas Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023) & (K Units)

Table 38. Americas Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2018-2023)

Table 39. Americas Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 40. Americas Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2018-2023)

Table 41. Americas Neuroblastoma Chemotherapy Drugs Sales by Type (2018-2023) & (K Units)

Table 42. Americas Neuroblastoma Chemotherapy Drugs Sales by Application

(2018-2023) & (K Units)

Table 43. APAC Neuroblastoma Chemotherapy Drugs Sales by Region (2018-2023) & (K Units)

Table 44. APAC Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2018-2023)

Table 45. APAC Neuroblastoma Chemotherapy Drugs Revenue by Region (2018-2023) & (\$ Millions)

Table 46. APAC Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2018-2023)

Table 47. APAC Neuroblastoma Chemotherapy Drugs Sales by Type (2018-2023) & (K Units)

Table 48. APAC Neuroblastoma Chemotherapy Drugs Sales by Application (2018-2023) & (K Units)

Table 49. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023) & (K Units)

Table 50. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2018-2023)

Table 51. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 52. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2018-2023)

Table 53. Europe Neuroblastoma Chemotherapy Drugs Sales by Type (2018-2023) & (K Units)

Table 54. Europe Neuroblastoma Chemotherapy Drugs Sales by Application (2018-2023) & (K Units)

Table 55. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2018-2023) & (K Units)

Table 56. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2018-2023)

Table 57. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 58. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2018-2023)

Table 59. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type (2018-2023) & (K Units)

Table 60. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application (2018-2023) & (K Units)

Table 61. Key Market Drivers & Growth Opportunities of Neuroblastoma Chemotherapy Drugs

Table 62. Key Market Challenges & Risks of Neuroblastoma Chemotherapy Drugs

Table 63. Key Industry Trends of Neuroblastoma Chemotherapy Drugs

Table 64. Neuroblastoma Chemotherapy Drugs Raw Material

Table 65. Key Suppliers of Raw Materials

Table 66. Neuroblastoma Chemotherapy Drugs Distributors List

Table 67. Neuroblastoma Chemotherapy Drugs Customer List

Table 68. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 69. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 70. Americas Neuroblastoma Chemotherapy Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 71. Americas Neuroblastoma Chemotherapy Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 72. APAC Neuroblastoma Chemotherapy Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 73. APAC Neuroblastoma Chemotherapy Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 74. Europe Neuroblastoma Chemotherapy Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 75. Europe Neuroblastoma Chemotherapy Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 76. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 77. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 78. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Type (2024-2029) & (K Units)

Table 79. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 80. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Application (2024-2029) & (K Units)

Table 81. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 82. Baxter Healthcare Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 83. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 84. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 85. Baxter Healthcare Main Business

Table 86. Baxter Healthcare Latest Developments

Table 87. Ingenus Pharmaceuticals Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 88. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 89. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 90. Ingenus Pharmaceuticals Main Business

Table 91. Ingenus Pharmaceuticals Latest Developments

Table 92. ANI Pharmaceuticals Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 93. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 94. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 95. ANI Pharmaceuticals Main Business

Table 96. ANI Pharmaceuticals Latest Developments

Table 97. Teva Pharmaceuticals Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 98. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 99. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 100. Teva Pharmaceuticals Main Business

Table 101. Teva Pharmaceuticals Latest Developments

Table 102. Qilu Pharmaceutical Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 103. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 104. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 105. Qilu Pharmaceutical Main Business

Table 106. Qilu Pharmaceutical Latest Developments

Table 107. Pfizer Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 108. Pfizer Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 109. Pfizer Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 110. Pfizer Main Business

Table 111. Pfizer Latest Developments

Table 112. Hikma Pharmaceuticals Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 113. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 114. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 115. Hikma Pharmaceuticals Main Business

Table 116. Hikma Pharmaceuticals Latest Developments

Table 117. Fresenius Kabi Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 118. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 119. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 120. Fresenius Kabi Main Business

Table 121. Fresenius Kabi Latest Developments

Table 122. Accord Healthcare Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 123. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 124. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 125. Accord Healthcare Main Business

Table 126. Accord Healthcare Latest Developments

Table 127. Viatris Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors

Table 128. Viatris Neuroblastoma Chemotherapy Drugs Product Portfolios and Specifications

Table 129. Viatris Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 130. Viatris Main Business

Table 131. Viatris Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Neuroblastoma Chemotherapy Drugs
- Figure 2. Neuroblastoma Chemotherapy Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Neuroblastoma Chemotherapy Drugs Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Neuroblastoma Chemotherapy Drugs Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Neuroblastoma Chemotherapy Drugs Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Cyclophosphamide
- Figure 10. Product Picture of Cisplatin or Carboplatin
- Figure 11. Product Picture of Vincristine
- Figure 12. Product Picture of Doxorubicin (Adriamycin)
- Figure 13. Product Picture of Etoposide
- Figure 14. Product Picture of Other
- Figure 15. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type in 2022
- Figure 16. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2018-2023)
- Figure 17. Neuroblastoma Chemotherapy Drugs Consumed in Hospital
- Figure 18. Global Neuroblastoma Chemotherapy Drugs Market: Hospital (2018-2023) & (K Units)
- Figure 19. Neuroblastoma Chemotherapy Drugs Consumed in Clinic
- Figure 20. Global Neuroblastoma Chemotherapy Drugs Market: Clinic (2018-2023) & (K Units)
- Figure 21. Neuroblastoma Chemotherapy Drugs Consumed in Other
- Figure 22. Global Neuroblastoma Chemotherapy Drugs Market: Other (2018-2023) & (K Units)
- Figure 23. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2022)
- Figure 24. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application in 2022
- Figure 25. Neuroblastoma Chemotherapy Drugs Sales Market by Company in 2022 (K

Units)

Figure 26. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Company in 2022

Figure 27. Neuroblastoma Chemotherapy Drugs Revenue Market by Company in 2022 (\$ Million)

Figure 28. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Company in 2022

Figure 29. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Geographic Region (2018-2023)

Figure 30. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Geographic Region in 2022

Figure 31. Americas Neuroblastoma Chemotherapy Drugs Sales 2018-2023 (K Units)

Figure 32. Americas Neuroblastoma Chemotherapy Drugs Revenue 2018-2023 (\$ Millions)

Figure 33. APAC Neuroblastoma Chemotherapy Drugs Sales 2018-2023 (K Units)

Figure 34. APAC Neuroblastoma Chemotherapy Drugs Revenue 2018-2023 (\$ Millions)

Figure 35. Europe Neuroblastoma Chemotherapy Drugs Sales 2018-2023 (K Units)

Figure 36. Europe Neuroblastoma Chemotherapy Drugs Revenue 2018-2023 (\$ Millions)

Figure 37. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales 2018-2023 (K Units)

Figure 38. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue 2018-2023 (\$ Millions)

Figure 39. Americas Neuroblastoma Chemotherapy Drugs Sales Market Share by Country in 2022

Figure 40. Americas Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country in 2022

Figure 41. Americas Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2018-2023)

Figure 42. Americas Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2018-2023)

Figure 43. United States Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 44. Canada Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 45. Mexico Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 46. Brazil Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 47. APAC Neuroblastoma Chemotherapy Drugs Sales Market Share by Region in 2022

Figure 48. APAC Neuroblastoma Chemotherapy Drugs Revenue Market Share by Regions in 2022

Figure 49. APAC Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2018-2023)

Figure 50. APAC Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2018-2023)

Figure 51. China Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Japan Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 53. South Korea Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Southeast Asia Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 55. India Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 56. Australia Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 57. China Taiwan Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 58. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country in 2022

Figure 59. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country in 2022

Figure 60. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2018-2023)

Figure 61. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2018-2023)

Figure 62. Germany Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 63. France Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 64. UK Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 65. Italy Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 66. Russia Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$

Millions)

Figure 67. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Country in 2022

Figure 68. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country in 2022

Figure 69. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2018-2023)

Figure 70. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2018-2023)

Figure 71. Egypt Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 72. South Africa Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Israel Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 74. Turkey Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 75. GCC Country Neuroblastoma Chemotherapy Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 76. Manufacturing Cost Structure Analysis of Neuroblastoma Chemotherapy Drugs in 2022

Figure 77. Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs

Figure 78. Industry Chain Structure of Neuroblastoma Chemotherapy Drugs

Figure 79. Channels of Distribution

Figure 80. Global Neuroblastoma Chemotherapy Drugs Sales Market Forecast by Region (2024-2029)

Figure 81. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Region (2024-2029)

Figure 82. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Forecast by Type (2024-2029)

Figure 83. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Type (2024-2029)

Figure 84. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Forecast by Application (2024-2029)

Figure 85. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Neuroblastoma Chemotherapy Drugs Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GED80B0FE4DEEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GED80B0FE4DEEN.html>